China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk

Dow Jones

2024-12-10

0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com)

(END) Dow Jones Newswires

December 09, 2024 21:50 ET (02:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2490030334"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490030334\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2490030334?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490030334","market":"hk","top_or_hot":-1,"title":"China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 21:50 ET (02:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Healthcare Sector's Recovery Momentum May Continue in 2025 -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-10 10:50</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2024 21:50 ET (02:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1807302812.USD","symbol_name":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490030334","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490030334","pubTimestamp":1733799000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK4505":"高瓴资本持仓","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK4504":"桥水持仓","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK4548":"巴美列捷福持仓","HCSG":"医疗保健服务","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK4137":"综合支持服务","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1589":"北水核心资产","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK4139":"生物科技","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","BK1583":"高瓴概念","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK4535":"淡马锡持仓","03692":"翰森制药","BK4526":"热门中概股","BK4588":"碎股","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","01093":"石药集团"},"translate_title":"2025年中国医疗保健行业复苏势头或将持续——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"03692":0.9,"BGNE":0.9,"HCSG":1},"content_text":"0250 GMT - The recovery momentum seen in China's healthcare companies since mid-August is expected to continue in 2025, says Cyrus Ng, an analyst at Deutsche Bank. The recovery should be helped by the Chinese government's supportive policy on innovative drugs and pricing, and an expected improvement in biotech funding, he says in a note. China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment, he notes. However, with improvement in sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025, he says. Ng's sector picks include Beigene, Hansoh and CSPC. (monica.gupta@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 21:50 ET (02:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}